close x

Manager, Corporate Communications

180 Attwell Drive, Suite 360
Toronto, ON, Canada
M9W 6A9
Tel: (416) 675-8280
Fax: (416) 675-8301
Email: ir@cangene.com

Need more contact information?

Investor Relations

Introduction

Symbol Value Date Time Change Volume
CNJ.TO 1.74 2/3/2012 1:12pm 0.00 4167
Click Here for Detailed Charts* courtesy of Yahoo!This link will send you outside of the Cangene website
Cangene's disclosure documents are also available on the SEDAR website.
Continue to the SEDAR websiteThis link will send you outside of the Cangene website

Corporate Profile

Cangene is a profitable and fully integrated developer and manufacturer of immune therapeutics, primarily targeting exigent infectious disease and biodefense applications. We have five products that have been approved in the United States and/or Canada and, with three products included in the U.S. Strategic National Stockpile, we have been a significant civilian suppliers to the U.S. government.

With nearly 30 years of experience making our lead drug, WinRho® SDF, manufacturing capability is one of Cangene's key strengths. We operate Health Canada- and FDA-inspected facilities in Canada as well as our contract-manufacturing subsidiary located in Baltimore, Maryland, Cangene bioPharma, Inc. Cangene bioPharma is also our U.S. commercial hub, housing our sales force and warehousing. Cangene collects a portion of the plasma used in the manufacture of its products through Cangene Plasma Resources, Inc.

Most of Cangene's products are hyperimmunes—purified antibody products that are specific for targets such as hepatitis B, botulism, and anthrax. In addition, we are developing monoclonal antibody technology and an anti-infective called immune globulin intravenous (IGIV).

Cangene has been listed on the Toronto Stock Exchange since 1991 under the symbol CNJ. The Company has operations in Manitoba and Ontario in Canada, and California, Maryland and Florida in the United States. The majority of our 700 employees work in Winnipeg or at Cangene bioPharma, Inc..

Cangene has been listed on the Toronto Stock Exchange since 1991 under the symbol CNJ. The Company has operations in Manitoba and Ontario in Canada, and California, Maryland and Florida in the United States. The majority of our 700 employees work in Winnipeg or at Cangene bioPharma, Inc., our subsidiary in Baltimore. Additional company information can be found at www.cangene.com, www.cangeneplasma.comThis link will send you outside of the Cangene website. and www.cangenebiopharma.com.This link will send you outside of the Cangene website.

 

ISO 9001- 2008 Certified
Copyright © 2009 Cangene All Rights Reserved
This page was last updated on: December 19, 2011